Effects of a New Formulation of Multiple-Action Tear Substitute on Objective Ocular Surface Parameters and Ocular Discomfort Symptoms in Patients with Dry Eye Disease.

Luca VigoCarlotta SenniMarco PellegriniAldo VaggeLorenzo Ferro DesideriFrancesco CaronesVincenzo ScorciaGiuseppe Giannaccare

Published in: Ophthalmology and therapy (2022)

Two-month treatment with Trimix formulation improved objective signs and subjective symptoms in patients with DED, showing also a good tolerability profile.

Keyphrases

sleep quality
drug delivery
open label
depressive symptoms
combination therapy
double blind
optic nerve